Compugen (NASDAQ:CGEN) Releases Earnings Results, Misses Estimates By $0.20 EPS

Compugen (NASDAQ:CGEN) released its quarterly earnings data on Tuesday. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.20), Zacks reports. Compugen had a net margin of 2.67% and a return on equity of 2.61%. The business had revenue of $17.13 million for the quarter, compared to analysts’ expectations of $17.67 million. During the same period last year, the business earned ($0.11) earnings per share.

Compugen Trading Down 1.9 %

NASDAQ CGEN traded down $0.03 during trading hours on Thursday, hitting $1.56. 85,021 shares of the company’s stock traded hands, compared to its average volume of 405,169. Compugen has a 52 week low of $0.58 and a 52 week high of $3.03. The firm has a market capitalization of $139.24 million, a P/E ratio of 79.50 and a beta of 2.64. The business’s fifty day moving average price is $1.77 and its two-hundred day moving average price is $1.88.

Analysts Set New Price Targets

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a report on Thursday, August 15th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.